Ensol Biosciences Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ensol Biosciences Inc.
Yuhan’s chief scientific officer shares why the leading Korean pharma firm is stepping up its open innovation activities and how this is helping to transform the company into a more global and R&D-based enterprise.
Major Korean firm Yuhan is seeing progress across multiple novel drug candidates licensed out to global partners, with two now entering pivotal trials. An innovative therapy for degenerative disc disease licensed to Spine BioPharma has received an FDA nod for a Phase III program and may change the standard of care for chronic low back pain patients.
- Artificial Intelligence
Drug Discovery Tools
- Drug Discovery Tools
- Other Names / Subsidiaries
- Ensoltek Co., Ltd
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.